PSUN48 Serum leptin levels among chronic kidney diseased subjects with hypertensive heart disease: An observational cross-sectional study

BACKGROUND: Chronic kidney disease (CKD) is one of the main health concerns in Sub-Saharan Africa. Leptin, a peptide hormone produced by the adipocytes have been observed to trigger complications such as cardiovascular diseases with significant mortality. The precise role of leptin in hypertension-mediated development of CKD is unknown. Research findings in this area have been inconsistent. The aim of the study was to evaluate serum leptin levels among CKD patients attending a tertiary referral hospital. METHODOLOGY: An observational cross-sectional study. One hundred and eight (108) participants took part in the study. A structured questionnaire was used to gather their anthropometric and demographic characteristics. Blood samples were obtained and analyzed for leptin and other biochemical parameters. RESULTS: There were significant differences in the plasma levels of leptin, glucose (FBG), creatinine and triglyceride among CKD subjects compared with controls (p <0.05 respectively). An inverse correlation was found for leptin vs estimated GFR (r = -0.505, p= 0.0001) among CKD subjects. In the CKD group, being at stage 5 made the largest unique contribution (beta = 0.47, p < 0.0001) to the variance in serum leptin levels, followed by HDL, FBG, HHD diagnosis of more than 6 years, female gender and BMI respectively (p< 0.05). In the control group, female gender made the largest unique contribution to circulating leptin levels (beta = 0.709, p < 0.0001) followed by BMI (beta = 0.341, p < 0.0001), and eGFR (beta = -0.222, p = 0.011). CONCLUSION: Serum leptin levels were significantly higher among CKD subjects co-burdened with hypertension heart disease in Accra. Stage 5 CKD was the most significant predictor of serum leptin levels. These findings underscore the role of leptin in the biochemical complexities observed in CKD subjects. Therapeutic strategies targeting leptin reduction are welcomed in the management of CKD. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.